MYLAN-CIPROFLOXACIN XL TABLET (EXTENDED-RELEASE)

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN)

Disponible desde:

MYLAN PHARMACEUTICALS ULC

Código ATC:

J01MA02

Designación común internacional (DCI):

CIPROFLOXACIN

Dosis:

500MG

formulario farmacéutico:

TABLET (EXTENDED-RELEASE)

Composición:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN) 500MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

QUINOLONES

Resumen del producto:

Active ingredient group (AIG) number: 0123207001; AHFS:

Estado de Autorización:

CANCELLED PRE MARKET

Fecha de autorización:

2016-11-02

Ficha técnica

_ _
_ _
_Page 1 of 54_
PRODUCT MONOGRAPH
Pr
MYLAN-CIPROFLOXACIN XL
(Ciprofloxacin hydrochloride and Ciprofloxacin Extended Release
Tablets)
Ciprofloxacin, 500 mg, 1000 mg
Antibacterial Agent
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Revision:
May 25, 2015
Submission Control No: 184540
_ _
_ _
_Page 2 of 54_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
15
DOSAGE AND ADMINISTRATION
.....................................................................................
21
OVERDOSAGE
.......................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 29
PART II: SCIENTIFIC INFORMATION
...............................................................................
30
PHARMACEUTICAL INFORMATION
.................................................................................
30
CLINICAL TRIALS
...................................................